Stanley H. Appel, MD, and Gary L. Pattee, MD, discuss RADICAVA ORS® data and their thoughts on what oral treatment means to patients.
See patient and caregiver experiences with RADICAVA®.
Learn moreExperienced neurologists provide their insights for considering RADICAVA® treatment that has been prescribed by nearly 2000 US HCPs since August 2017.1 a (see footnote)
Providers are paid consultants.
Stanley H. Appel, MD, and Gary L. Pattee, MD, discuss RADICAVA ORS® data and their thoughts on what oral treatment means to patients.
Nationwide Webcast Video Discussion About a Treatment in ALS
Ghazala Hayat, MD, FAAN, explains why she recommends RADICAVA® for all of her patients who are newly diagnosed with ALS and how the inclusion criteria from the pivotal trial impacts her decision to prescribe treatment.
Considerations When Prescribing
Melanie Taylor, MD, describes her approach to discussing treatment options for ALS, the patients she considers for RADICAVA® treatment, and the importance of patients hearing about their treatment options from a healthcare provider.
Patient Selection for RADICAVA® (edaravone)
Said Beydoun, MD, FAAN, discusses clinical trial results of RADICAVA®, his use of the ALSFRS-R with his patients, and the challenges that have faced previous ALS clinical trials and how newer clinical trials are addressing them.
The Efficacy of RADICAVA®
Melanie Taylor, MD, shares her approach to treating patients with ALS, educating them on the disease state and their treatment options, including how RADICAVA® may help slow the loss of their physical function.
Physician-Patient Treatment Discussions
Tomas Holmlund, MD, shares advice for handling in-office practicalities with RADICAVA®, including insurance and product access, and he explains why some of his patients prefer receiving treatment at an infusion center.
Incorporating RADICAVA® Into Your Treatment Considerations
Melanie Taylor, MD, reviews the efficacy, safety, and data from the pivotal clinical trial of RADICAVA®, explains her experience in starting a patient on treatment and the options for treatment locations, considerations around clinical trials and prescribing RADICAVA®, and how she approaches the treatment discussion with patients.
Peer Perspective on Prescribing RADICAVA® (edaravone)
Tomas Holmlund, MD, discusses the safety profile of RADICAVA® and how it impacts his decision to prescribe treatment.
Safety and Personal Experience When Prescribing
See patient and caregiver experiences with RADICAVA®.
Learn moreAdd your practice to our ALS Care Locator.
A panel of ALS experts discuss the benefits, risks, and appropriate uses of RADICAVA ORS® or RADICAVA® IV.
Providers are paid consultants.
Clinical Professor, Department of Neurology
Herbert Wertheim College of Medicine
Florida International University
Miami, Florida
University of Texas Health Science Center
San Antonio, Texas
California Pacific Medical Center
San Francisco, California
Learn about the ALS Functional Rating Scale-Revised (ALSFRS-R), the measure used to evaluate the clinical efficacy of RADICAVA®.
ALS Functional Rating Scale-Revised
Review information on the pivotal trial of RADICAVA® in ALS, including the clinical development program, key inclusion criteria, and baseline patient characteristics.
Pivotal Trial in ALS
Hear about primary efficacy endpoint data and safety information from the pivotal trial of RADICAVA®.
Efficacy and Safety
aBased on RADICAVA ORS® and RADICAVA® IV prescriptions submitted in the US as of September 2022. Not independently verified. Return to content
Reference: 1. Data on file. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.
Explore detailed results of the pivotal trials that were discussed.
RADICAVA (edaravone) and RADICAVA ORS (edaravone) are contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred with RADICAVA.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA or RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA-treated patients were contusion (15%), gait disturbance (13%), and headache (10%). In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA and RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information.
RADICAVA (edaravone) and RADICAVA ORS (edaravone) are contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred with RADICAVA.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA or RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA and RADICAVA ORS contain sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%) reported in RADICAVA-treated patients were contusion (15%), gait disturbance (13%), and headache (10%). In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA and RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Please see full Prescribing Information.
You are leaving this website, hosted by Mitsubishi Tanabe Pharma America.
This link may take you to a website to which our Privacy Policy does not apply.
Mitsubishi Tanabe Pharma America does not control the content of third-party sites.